FDA approves Genzyme pediatric leukemia drug

12/30/2004 | Wall Street Journal, The

The FDA approved Genzyme's leukemia drug, Clolar, assigning orphan status to the drug developed for treating patients age 21 and younger who do not respond to chemotherapy. Genzyme expects the drug to be available in January, at an estimated price of $34,000 per dose. One expert said it is likely the drug also will be used off-label in combination with other treatments for adult patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN